What a Mixed Midterm Result Could Mean for These 2 Health Care ETFs

Impact · against what's priced in

The article provides no new catalysts for the large-cap healthcare names, as the anticipation of legislative gridlock and the resulting regulatory status quo are already baked into current valuations. While the ETFs show strong YTD momentum, the fundamental drivers for LLY, JNJ, and UNH remain unchanged by the prediction of a divided government.

JNJ+0.00: Already priced in
The price assumes: current 20.9% free cash flow margin

What a Mixed Midterm Result Could Mean for These 2 Health Care ETFs

What matters in this story

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication

What a Mixed Midterm Result Could Mean for These 2 Health Care ETFs

What matters in this story

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication

How each ticker is affected

Connected tickers

Track these names every morning.

Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.

Bayer: Turnaround Is Gaining Momentum, But Debt Remains A Risk

HIMS DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HIMS

Metis TechBio inks up to $1.1 billion deal with Eli Lilly for drug delivery tech

What a Mixed Midterm Result Could Mean for These 2 Health Care ETFs

What matters in this story

Next reads from the same story arc

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication

What a Mixed Midterm Result Could Mean for These 2 Health Care ETFs

What matters in this story

Next reads from the same story arc

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication

How each ticker is affected

Connected tickers

Track these names every morning.

Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.

Bayer: Turnaround Is Gaining Momentum, But Debt Remains A Risk

HIMS DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HIMS

Metis TechBio inks up to $1.1 billion deal with Eli Lilly for drug delivery tech